Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 20, 2026

Are ServiceNow’s New AI Integrations Quietly Redefining Its Platform Moat for Investors in NOW?

View original at finance.yahoo.com
Are ServiceNow’s New AI Integrations Quietly Redefining Its Platform Moat for Investors in NOW?…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • ServiceNow's forecasts yield a $141.86 fair value, a 35% upside to its current price.

    60% confidence

  • ServiceNow's narrative projects $23.6 billion revenue and $4.0 billion earnings by 2029.

    60% confidence

  • The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it.

    60% confidence

  • To own ServiceNow today, investors need to believe its AI Platform becomes core plumbing for enterprise workflows, supporting durable subscription growth despite sharp share price declines and AI disruption worries.

    60% confidence

  • Reaching the 2029 projection requires 19.1% yearly revenue growth and a $2.2 billion earnings increase from $1.8 billion.

    60% confidence

  • The biggest risk to ServiceNow remains execution in AI and new workflows, where rapid change and strong competition could pressure both growth and margins.

    60% confidence

Data points we hold from this source

ServiceNow · upside potential35 percent
ServiceNow · fair value141.86 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Are ServiceNow’s New AI Integrations Quietly Redefining Its Platform Moat for Investors in NOW? — Source | Via News | ViaNews Market